Osteoporosis: The Evidence-Based Supplement Protocol

← Back to articles

Established osteoporosis — a T-score of -2.5 or below, or a fragility fracture — is treated with prescription drugs that have proven fracture reduction: bisphosphonates, denosumab, and anabolic agents such as teriparatide and romosozumab. Supplements do not belong in the same tier. Their evidence-based role is narrower: ensuring the nutritional substrate (calcium and vitamin D) that those drugs and bone itself depend on, supporting fall prevention, and — debatably — adding vitamin K2. The honest framing, echoed by the National Osteoporosis Foundation guideline, is that calcium and vitamin D are adjuncts to be combined with weight-bearing exercise and, where indicated, pharmacotherapy — not a stand-alone substitute (Cosman 2014). This protocol also flags a real safety trade-off that fertility- and bone-supplement marketing usually omits: more calcium is not better.

Calcium — Meet the Requirement, Don't Exceed It (Moderate Evidence, With a Caveat)

The recommended intake is about 1,000 mg/day for most adults and 1,200 mg/day for women over 50 and men over 70. The key word is meet: aim to reach the target primarily through diet, and supplement only the shortfall. In the Women's Health Initiative, calcium 1,000 mg plus vitamin D 400 IU produced only a small (about 1%) gain in hip bone density, did not significantly reduce hip fractures in the overall intention-to-treat analysis, and increased the risk of kidney stones (Jackson 2006). Separately, a meta-analysis found that calcium supplements taken without vitamin D were associated with a roughly 30% higher risk of myocardial infarction (Bolland 2010) — a signal that remains debated but argues against routinely megadosing calcium. Grade: moderate for correcting inadequate intake; against supplementing beyond requirements. If you supplement, keep single doses at or below 500 mg; calcium citrate is absorbed adequately with or without food. See our calcium harm/benefit piece.

Vitamin D3 — Correct Deficiency (Strong for Adequacy, Not for Routine High Dose)

Vitamin D is required for intestinal calcium absorption and contributes to muscle function and fall prevention. But the large VITAL trial showed that vitamin D 2,000 IU/day did not reduce total, non-vertebral, or hip fractures in generally healthy adults who were not selected for deficiency or low bone mass (LeBoff 2022). The lesson is precise: the benefit is in correcting a deficiency, not in adding vitamin D to people who already have enough. Vitamin D3 is the preferred form. Grade: strong for deficiency correction; not supported for routine high-dose use in replete adults. Test serum 25-OH-D and dose to restore adequacy (commonly 800–2,000 IU/day); see our vitamin D piece.

Vitamin K2 (MK-7) — 90–180 mcg Daily (Limited/Debated Evidence)

Vitamin K2 is a cofactor for carboxylation of osteocalcin, the protein that helps bind calcium into bone matrix. In a 3-year RCT of 244 healthy postmenopausal women, MK-7 180 mcg/day slowed the age-related decline in bone mineral density at the lumbar spine and femoral neck (but not total hip) versus placebo (Knapen 2013; the maker of an MK-7 ingredient supported the work). A 2022 meta-analysis of 16 RCTs in 6,425 postmenopausal women found K2 improved lumbar-spine BMD; its effect on actual fracture incidence was not significant overall and became significant only after one heterogeneous study was excluded — i.e., the fracture evidence is unsettled (Ma 2022). Grade: limited and debated — a reasonable optional adjunct, not a proven fracture-preventer. Important caution: K2 antagonizes warfarin; anyone on a vitamin-K-antagonist anticoagulant should not start it without their anticoagulation team's input.

Magnesium — Adequacy Only (Insufficient Trial Evidence)

About 60% of the body's magnesium resides in bone, and low intake is associated with lower bone density in observational data. But there is little randomized evidence that magnesium supplementation reduces fractures, so the defensible goal is simply nutritional adequacy rather than therapeutic dosing. Grade: insufficient for fracture outcomes. Glycinate or citrate forms are well tolerated; see our magnesium glycinate piece.

What Doesn't Work / Overhyped

Strontium deserves a specific warning. The prescription drug strontium ranelate showed BMD benefit but was restricted in Europe over cardiovascular and skin-reaction risks; the over-the-counter supplement forms (strontium citrate) have no equivalent fracture-reduction data and, because strontium is denser than calcium, they artificially inflate DXA bone-density readings — making the scan look better while telling you nothing reliable. "Bone-building" megaformulas rarely add anything beyond the calcium, vitamin D, and K2 already discussed. Bone broth and collagen do not meaningfully raise bone mineral density. And no supplement regimen substitutes for drug therapy once osteoporosis is established — supplement-only management does not match the fracture reduction of bisphosphonates or denosumab.

How to Run the Protocol

Begin with a baseline DXA scan, a serum 25-OH-D level, and an honest estimate of dietary calcium. Make weight-bearing and resistance exercise the cornerstone — it is the most effective non-pharmacological intervention and supports everything else. Reach the calcium target mainly through food, supplementing only the gap and keeping single doses modest. Correct vitamin D if you are deficient. Consider MK-7 90–180 mcg/day as an optional adjunct (never alongside warfarin without supervision), and ensure adequate magnesium. Re-assess DXA roughly every two years. Crucially, if your T-score is -2.5 or below, or you have had a fragility fracture, prescription therapy is first-line and these supplements are supportive players, not the treatment. See the bone density stack for the combined approach.